huIL33/huIL33R Mouse
製品名
huIL33/huIL33R Mouse
製品ID
C002039
系統名
C57BL/6NCya-Il33em1(hIL33)Il1rl1em1(hIL1RL1)/Cya
背景情報
C57BL/6NCya
状況
このマウス系統を論文で使用する場合は、「huIL33/huIL33R Mouse（カタログ番号C002039）はサイアジェンから購入しました。」と引用してください。
製品タイプ
年齢
遺伝子型
性別
数量
遺伝子別名
DVS27, IL1F11, NF-HEV, NFEHEV, C9orf26, T1, ST2, DER4, ST2L, ST2V, FIT-1, IL33R
染色体
Chr 9, Chr 2
MGI ID
さらに
系統詳細
IL33 encodes interleukin-33 (IL-33), a member of the IL-1 cytokine family that functions as an important endogenous alarmin in the immune system [1]. IL-33 is mainly released by barrier tissue cells, such as epithelial cells and endothelial cells, under conditions including mechanical injury, pathogen infection, or oxidative stress. It binds to the IL1RL1/ST2 receptor complex expressed on the surface of various immune cells, including Th2 cells, mast cells, basophils, eosinophils, and group 2 innate lymphoid cells (ILC2s), thereby initiating downstream signaling cascades.
Interleukin-1 receptor-like protein 1 (IL1RL1), also known as ST2 or IL33R, is a member of the interleukin-1 receptor superfamily and serves as the specific receptor for IL-33, playing a critical role in inflammatory responses and immune regulation [2]. The IL1RL1 gene encodes two major protein isoforms: the transmembrane receptor ST2L and the soluble receptor sST2. Functional ST2L is primarily expressed on the surface of various cell types, including immune cells (such as mast cells, helper T cells, and eosinophils), epithelial cells, and endothelial cells [2]. Upon IL-33 stimulation, ST2L activation triggers downstream inflammatory signaling pathways, including NF-κB and MAPK pathways, promoting the release of cytokines and chemokines and participating in various biological processes, including type 2 inflammatory responses, fibrosis, and tumor microenvironment regulation [2-5]. The IL-33/IL1RL1 signaling pathway exhibits complex roles in cancer, potentially promoting tumor cell proliferation, metastasis, and angiogenesis, while also activating antitumor immunity and suppressing tumor growth [3].
The huIL33/huIL33R mouse is a dual-target humanized model obtained by crossing the huIL33 mouse (Catalog No.: C001722) with the huIL1RL1(IL33R) mouse (Catalog No.: C001632). This model is applicable for studying the pathogenesis of inflammatory diseases, including asthma, atopic dermatitis (AD), allergic rhinitis, and inflammatory bowel disease (IBD), as well as tumor-related diseases. It can also be used for the screening, development, and preclinical pharmacodynamic and safety evaluation of therapeutics targeting the IL-33/IL1RL1 pathway.
参考文献
Shakerian L, Kolahdooz H, Garousi M, Keyvani V, Kamal Kheder R, Abdulsattar Faraj T, Yazdanpanah E, Esmaeili SA. IL-33/ST2 axis in autoimmune disease. Cytokine. 2022 Oct;158:156015.
Griesenauer B, Paczesny S. The ST2/IL-33 Axis in Immune Cells during Inflammatory Diseases. Front Immunol. 2017 Apr 24;8:475.
Andreone S, Gambardella AR, Mancini J, Loffredo S, Marcella S, La Sorsa V, Varricchi G, Schiavoni G, Mattei F. Anti-Tumorigenic Activities of IL-33: A Mechanistic Insight. Front Immunol. 2020 Nov 30;11:571593.
Yi XM, Li M, Chen YD, Shu HB, Li S. Reciprocal regulation of IL-33 receptor-mediated inflammatory response and pulmonary fibrosis by TRAF6 and USP38. Proc Natl Acad Sci U S A. 2022 Mar 8;119(10):e2116279119.
Saikumar Jayalatha AK, Hesse L, Ketelaar ME, Koppelman GH, Nawijn MC. The central role of IL-33/IL-1RL1 pathway in asthma: From pathogenesis to intervention. Pharmacol Ther. 2021 Sep;225:107847.
系統作製戦略
The huIL33/huIL33R mouse is a dual-target humanized model obtained by crossing the huIL33 mouse (Catalog No.: C001722) with the huIL1RL1(IL33R) mouse (Catalog No.: C001632).
Figure 1. Gene editing strategy of huIL33 mice. The sequences from start codon to stop codon of the endogenous mouse Il33 gene were replaced with the sequences from start codon to stop codon of the human IL33 gene.
Figure 2. Gene editing strategy of huIL1RL1(IL33R) mice. The mouse Il1rl1 signal peptide and endogenous extracellular domain were replaced with the human IL1RL1 signal peptide and extracellular domain. The murine transmembrane and cytoplasmic domains were preserved.
適用分野
Pathogenesis studies of inflammatory diseases, including asthma, atopic dermatitis (AD), allergic rhinitis, and inflammatory bowel disease (IBD), as well as tumor-related diseases;
Screening, development, and preclinical pharmacodynamic and safety evaluation of therapeutics targeting the IL-33/IL1RL1 pathway.
お問い合わせ
カスタムの動物モデルに関するご相談は、下記のフォームにご記入いただき、ご連絡いただくか見積もりをご依頼ください。
Cyagenはお客様のプライバシーを大変重視しています。当社の最新の製品や情報をお届けしたいと思っています。お客様の設定をご確認ください。
これらの配信はいつでも解除できます。配信停止方法およびデータ保護の詳細は プライバシーポリシー をご確認ください。
以下のボタンをクリックすることで、このフォームにご入力いただいた個人情報をCyagenが保存・処理し、ご要望のコンテンツを提供することに同意されたことになります。